Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › R&D spending
Tonix Pharmaceuticals Holding (TNXP) R&D spending by quarter
Tonix Pharmaceuticals Holding's R&D spending was $19.4M in Q2 2026 (second quarter 2026), +7% from Q1 2026. Over the last 7 quarters it ranged from $7.4M (Q1 2025) to $19.4M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $19.4M | +7% | +79% |
| Q1 2026 | $18.2M | +8% | +145% |
| Q4 2025 | $16.9M | +82% | +104% |
| Q3 2025 | $9.3M | -14% | — |
| Q2 2025 | $10.8M | +46% | — |
| Q1 2025 | $7.4M | -10% | — |
| Q4 2024 | $8.3M | — | — |
Q2 2026 at a glance
Tonix Pharmaceuticals Holding, Q2 2026: revenue $13.5M (+578% year over year), operating margin -314.1%, net loss $40.6M, operating cash flow −$42.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Tonix Pharmaceuticals Holding's R&D spending?
Tonix Pharmaceuticals Holding's R&D spending was $19.4M in Q2 2026 (second quarter 2026), +7% from Q1 2026.
How has Tonix Pharmaceuticals Holding's R&D spending changed?
Over the last 7 quarters it ranged from $7.4M (Q1 2025) to $19.4M (Q2 2026).
Q2 2026 results → · How Tonix Pharmaceuticals Holding makes money →